GleamWall
中文EN

DSGN Design Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1807120 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-9.8%
TTM EPS YoY-0.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-36.9%
ROA-34.6%
ROIC (approx.)-35.0%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets6.7%
Debt / equity0.00x
Current ratio16.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$59.13M$44.35M
SG&A expense$20.34M$18.03M
Operating income-$79.47M-$62.38M
Income tax$0$0
Net income-$69.79M-$49.59M
EBITDA-$78.84M-$61.79M
EPS (basic)-1.22-0.88
EPS (diluted)-1.22-0.88
Weighted avg. shares (diluted)57.33M56.59M
Balance sheet
Cash & equivalents$16.86M$22.56M
Short-term investments$202.99M$222.91M
Current assets$223.78M$248.04M
PP&E, net$981,000$1.41M
Total assets$226.20M$252.09M
Current liabilities$13.05M$8.46M
Total liabilities$13.70M$10.00M
Shareholders' equity$212.50M$242.10M
Shares outstanding60.40M56.75M
Cash flow statement
Operating cash flow-$54.36M-$43.10M
Capital expenditure$193,000$340,000
Free cash flow-$54.55M-$43.45M
Investing cash flow$22.91M$43.95M
Financing cash flow$25.74M$513,000
Depreciation & amortization$622,000$596,000
Stock-based compensation$14.55M$13.07M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.